Matches in Wikidata for { <http://www.wikidata.org/entity/Q92492633> ?p ?o ?g. }
- Q92492633 description "article scientifique publié en 2020" @default.
- Q92492633 description "articolo scientifico (pubblicato il 2020)" @default.
- Q92492633 description "artigo científico (publicado na 2020)" @default.
- Q92492633 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q92492633 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q92492633 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92492633 description "scientific article published on 01 January 2020" @default.
- Q92492633 description "wetenschappelijk artikel" @default.
- Q92492633 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q92492633 description "научна статия" @default.
- Q92492633 name "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 name "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 name "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 type Item @default.
- Q92492633 label "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 label "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 label "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 prefLabel "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 prefLabel "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 prefLabel "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 P1433 Q92492633-4CDCD60E-3D73-44C7-A833-694D1612F86C @default.
- Q92492633 P1476 Q92492633-3B524E2C-7A1B-4F31-ABDC-92502BA79423 @default.
- Q92492633 P2093 Q92492633-0664E3F1-1806-4386-99F7-654C6F913283 @default.
- Q92492633 P2093 Q92492633-3A9945A7-9E51-4CAF-A6F2-89CA9FAA01CB @default.
- Q92492633 P2093 Q92492633-3AC0FD06-85AA-4971-8D65-7711C4BDDD60 @default.
- Q92492633 P2093 Q92492633-4A0F5E2E-BDFE-4F1C-AC70-43560F0D411B @default.
- Q92492633 P2093 Q92492633-5B293D11-0C70-4CC6-AD4F-F9F9DFE06EA0 @default.
- Q92492633 P2093 Q92492633-98295008-E7B0-41C7-9B68-D19AEDC0DD2E @default.
- Q92492633 P2093 Q92492633-E9CA9A8B-726D-476D-B233-5B5D7D0BD9DC @default.
- Q92492633 P2093 Q92492633-F17E14A1-1448-4575-B102-1F1A7E8BDF2D @default.
- Q92492633 P2093 Q92492633-F82EB7B1-2449-478C-9FA2-9767D8CD9EA5 @default.
- Q92492633 P2860 Q92492633-10777B18-6E50-4D58-95F8-5B570E0A5E36 @default.
- Q92492633 P2860 Q92492633-13168B3B-D90E-4A1C-8F29-68CE4AD2BD7E @default.
- Q92492633 P2860 Q92492633-1E9F3A08-7FCA-41B1-91A8-FCFAA90F709D @default.
- Q92492633 P2860 Q92492633-203E7C30-B5E8-4D8B-9620-159AE0C0630B @default.
- Q92492633 P2860 Q92492633-39AD57B0-044E-437B-82AF-02D3B44E4C0F @default.
- Q92492633 P2860 Q92492633-3BD2BDF2-E44A-49D5-A1A1-040B46A87D60 @default.
- Q92492633 P2860 Q92492633-5B9493EF-9D44-41B3-B7B9-70D021BDEAC1 @default.
- Q92492633 P2860 Q92492633-62C60C25-E16A-4A6D-85C2-9B644A48BA9D @default.
- Q92492633 P2860 Q92492633-68393871-BD30-41FB-97C1-C726D6BCA300 @default.
- Q92492633 P2860 Q92492633-776B615B-666B-41AB-AD1D-03F03B90DA58 @default.
- Q92492633 P2860 Q92492633-793ED719-98C7-4137-A274-523C2F560614 @default.
- Q92492633 P2860 Q92492633-86C2CC64-EF3A-43C6-BFA4-2B4348AA6601 @default.
- Q92492633 P2860 Q92492633-8BA0B449-29FA-4DB4-AA0F-784AE46537C1 @default.
- Q92492633 P2860 Q92492633-933BEEB5-6C57-438A-8EEF-13A5EA01D220 @default.
- Q92492633 P2860 Q92492633-9ABD2D22-0FDA-4141-A18C-C7ED1D3139E3 @default.
- Q92492633 P2860 Q92492633-A3ED86AF-5196-489A-BACD-ADE36A4DAF8D @default.
- Q92492633 P2860 Q92492633-A719DFC9-0F49-42AA-8539-D3DE83DB68B7 @default.
- Q92492633 P2860 Q92492633-B904CE6E-6086-4172-B41B-E9B2EBF6CE42 @default.
- Q92492633 P2860 Q92492633-BE8620E5-4249-4D5A-B53A-961F8F769862 @default.
- Q92492633 P2860 Q92492633-BEF3B537-3626-4715-B65A-77307144F370 @default.
- Q92492633 P2860 Q92492633-C0F1AF7D-4420-4956-91FD-A3C49F362849 @default.
- Q92492633 P2860 Q92492633-D22E9222-F694-4751-9E13-44B5C75E1E0B @default.
- Q92492633 P2860 Q92492633-D95DBB02-2745-46AF-B86F-8D3A10B1BFCE @default.
- Q92492633 P2860 Q92492633-DDDA299C-042B-4C09-9BE5-BB52F31E8BDA @default.
- Q92492633 P2860 Q92492633-E49C7EF8-6511-4BCE-9D81-2C3066D58AC4 @default.
- Q92492633 P2860 Q92492633-E4B26583-DF0B-45EF-A06C-5A55EECA86B7 @default.
- Q92492633 P304 Q92492633-2641B789-93BF-42CD-88DA-51461B8CA774 @default.
- Q92492633 P31 Q92492633-A08F3AB4-B948-41C5-B836-FB5B063A28CE @default.
- Q92492633 P356 Q92492633-9935ED4D-F83F-4982-9BF8-F906CD1269AD @default.
- Q92492633 P433 Q92492633-2AA518DB-55BC-43EF-ACCF-68713FD2653C @default.
- Q92492633 P478 Q92492633-484BB853-2BC6-4076-8111-3C97A3239373 @default.
- Q92492633 P50 Q92492633-7AAB5247-54DE-4284-A9E8-D1E2B3B9964B @default.
- Q92492633 P577 Q92492633-F09CB28B-2563-4536-8B21-858591C4608C @default.
- Q92492633 P698 Q92492633-261944A5-4CC6-4614-850E-DB9F9B0922E1 @default.
- Q92492633 P921 Q92492633-334CC678-307E-46AA-9BC2-C1FC3664B58D @default.
- Q92492633 P932 Q92492633-74BCCEAC-5F0E-43C4-99E4-F4DA00C80BD6 @default.
- Q92492633 P356 HEAD.13682 @default.
- Q92492633 P698 31913519 @default.
- Q92492633 P1433 Q5689497 @default.
- Q92492633 P1476 "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial" @default.
- Q92492633 P2093 "Jessica Ailani" @default.
- Q92492633 P2093 "Joel M Trugman" @default.
- Q92492633 P2093 "Kaifeng Lu" @default.
- Q92492633 P2093 "Kerry Knievel" @default.
- Q92492633 P2093 "Lawrence Severt" @default.
- Q92492633 P2093 "Matthew Butler" @default.
- Q92492633 P2093 "Michelle Finnegan" @default.
- Q92492633 P2093 "Sung Yun Yu" @default.
- Q92492633 P2093 "Susan Hutchinson" @default.
- Q92492633 P2860 Q28374440 @default.
- Q92492633 P2860 Q30570062 @default.
- Q92492633 P2860 Q31900950 @default.
- Q92492633 P2860 Q34173953 @default.
- Q92492633 P2860 Q34471863 @default.
- Q92492633 P2860 Q37695402 @default.
- Q92492633 P2860 Q37785745 @default.
- Q92492633 P2860 Q38378898 @default.
- Q92492633 P2860 Q39336637 @default.
- Q92492633 P2860 Q40774462 @default.
- Q92492633 P2860 Q41689462 @default.
- Q92492633 P2860 Q42700327 @default.
- Q92492633 P2860 Q44851293 @default.
- Q92492633 P2860 Q44986746 @default.
- Q92492633 P2860 Q45018129 @default.
- Q92492633 P2860 Q47556289 @default.
- Q92492633 P2860 Q50801832 @default.
- Q92492633 P2860 Q55084349 @default.
- Q92492633 P2860 Q56627246 @default.
- Q92492633 P2860 Q57197694 @default.